Today the recently founded company ADx NeuroSciences NV entered into a license agreement with KU Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases.